Table 1.
Patient characteristics
| CHF n = 82 018 |
CHF using spironolactone n = 12,344 |
|
|---|---|---|
| Age group | ||
| <20 | 518 (0.6%) | 11 (0.1%) |
| 20-39 | 1,366 (1.7%) | 62 (0.5%) |
| 40-59 | 6,114 (7.5%) | 716 (5.8%) |
| 60-79 | 31,499 (38.4%) | 5,093 (41.3%) |
| 80+ | 42,521 (51.8%) | 6,462 (52.3%) |
| Average age (SD) | 77.2 (14.1) | 78.5 (11.4) |
| Gender | ||
| - male | 39,132 (47.7%) | 6,368 (51.6%) |
| - Female | 42,886 (52.3%) | 5,976 (48.4%) |
| Average Von Korff score (SD) | 7.6 (3.4) | 8.8 (2.9) |
| Selected drug use | ||
| - ACE | 49,140 (59.9%) | 9,493 (76.9%) |
| - ARB | 23,326 (28.4%) | 4,455 (36.1%) |
| - β-blocker | 48,772 (59.5%) | 9,260 (75.0%) |
| Concomitant use with | ||
| - ACE | 6,702 (54.3%) | |
| - ARB | 2,654 (21.5%) | |
| - β-blocker | 7,217 (58.5%) | |